Walter MD - Anavex Life Chief Officer

AVXL Stock  USD 9.11  0.09  1.00%   

Insider

Walter MD is Chief Officer of Anavex Life Sciences
Address 630 5th Avenue, New York, NY, United States, 10111
Phone844 689 3939
Webhttps://www.anavex.com

Anavex Life Management Efficiency

The company has return on total asset (ROA) of (0.2043) % which means that it has lost $0.2043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3003) %, meaning that it created substantial loss on money invested by shareholders. Anavex Life's management efficiency ratios could be used to measure how well Anavex Life manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.29. Return On Capital Employed is expected to rise to -0.43 this year. At this time, Anavex Life's Total Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 186.4 M this year, although the value of Other Assets will most likely fall to about 3.7 M.
Anavex Life Sciences currently holds 12.53 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Anavex Life Sciences has a current ratio of 14.65, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Anavex Life's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Nadav MDCassava Sciences
81
Friedrich MDIovance Biotherapeutics
57
MBA MBABiovie Inc
58
MD MPHEyenovia
48
CPA MBAKodiak Sciences
60
Anna MooreTranscode Therapeutics
62
Esq JDIovance Biotherapeutics
48
Mark WhiteAnnovis Bio
68
James MDCassava Sciences
71
Chetan LathiaBioXcel Therapeutics
N/A
Howard MBAIovance Biotherapeutics
64
Laxminarayan BhatReviva Pharmaceuticals Holdings
59
Michael EsqTG Therapeutics
58
MD BScBioXcel Therapeutics
53
Kevin PharmDAxsome Therapeutics
46
Iris FrancesconiBioXcel Therapeutics
N/A
MBA MBAExelixis
48
Reid McCarthyAnnovis Bio
66
Bren KernEyenovia
43
Remy SukhijaMadrigal Pharmaceuticals
52
John IIINovavax
58
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company was incorporated in 2004 and is headquartered in New York, New York. Anavex Lf operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. Anavex Life Sciences (AVXL) is traded on NASDAQ Exchange in USA. It is located in 630 5th Avenue, New York, NY, United States, 10111 and employs 40 people. Anavex Life is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Anavex Life Sciences Leadership Team

Elected by the shareholders, the Anavex Life's board of directors comprises two types of representatives: Anavex Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anavex. The board's role is to monitor Anavex Life's management team and ensure that shareholders' interests are well served. Anavex Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anavex Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Principal Treasurer
David RPh, Senior Affairs
Juan MD, Senior Development
Stephan Toutain, Senior Vice President - Operations
Dr RPh, VP Affairs
Kun Jin, Head Biostatistics
Terrie Kellmeyer, Senior Development
MD MPH, Chief Officer
Walter MD, Chief Officer
MS MBA, Senior COO
Adebayo Laniyonu, Senior Development
CGA CPA, Principal Treasurer
Clint Tomlinson, VP Corporate
MBA MS, President, Chairman

Anavex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anavex Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anavex Life Sciences is a strong investment it is important to analyze Anavex Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Anavex Life's future performance. For an informed investment choice regarding Anavex Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Return On Assets
(0.20)
Return On Equity
(0.30)
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.